Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded by Wall Street Zen to “Sell” Rating

Ultragenyx Pharmaceutical (NASDAQ:RARE) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

RARE has been the topic of several other research reports. Truist Financial upgraded Ultragenyx Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. Canaccord Genuity Group dropped their target price on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Wedbush lowered their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $61.00 to $25.00 in a research report on Tuesday, March 24th. Finally, HC Wainwright lowered their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $59.56.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $21.91 on Friday. Ultragenyx Pharmaceutical has a 52-week low of $18.29 and a 52-week high of $42.37. The firm has a market capitalization of $2.16 billion, a PE ratio of -3.59 and a beta of 0.37. The business’s 50-day simple moving average is $23.69 and its 200 day simple moving average is $25.46.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. During the same quarter in the previous year, the company posted ($1.57) EPS. The business’s revenue was down 2.2% on a year-over-year basis. On average, research analysts forecast that Ultragenyx Pharmaceutical will post -4.57 earnings per share for the current year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, Director Shehnaaz Suliman sold 5,740 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $25.12, for a total transaction of $144,188.80. Following the transaction, the director owned 27,951 shares of the company’s stock, valued at $702,129.12. The trade was a 17.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Howard Horn sold 4,683 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $24.90, for a total value of $116,606.70. Following the completion of the transaction, the chief financial officer directly owned 110,342 shares in the company, valued at $2,747,515.80. The trade was a 4.07% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 20,103 shares of company stock worth $478,186. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Ultragenyx Pharmaceutical by 14.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after purchasing an additional 29,984 shares during the last quarter. Creative Planning acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $454,000. American Century Companies Inc. acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $366,000. M&T Bank Corp grew its position in shares of Ultragenyx Pharmaceutical by 19.7% in the second quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock valued at $263,000 after purchasing an additional 1,192 shares during the last quarter. Finally, Amundi grew its position in shares of Ultragenyx Pharmaceutical by 1,560.4% in the second quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock valued at $3,913,000 after purchasing an additional 93,189 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.